HEREDITARY HEMORRHAGIC TELANGIECTASIA
Clinical trials for HEREDITARY HEMORRHAGIC TELANGIECTASIA explained in plain language.
Never miss a new study
Get alerted when new HEREDITARY HEMORRHAGIC TELANGIECTASIA trials appear
Sign up with your email to follow new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a cancer drug stop the bleeding in HHT? new trial aims to find out.
Disease control OngoingThis study tests whether bevacizumab, a drug that blocks blood vessel growth, can reduce chronic bleeding and iron deficiency anemia in people with hereditary hemorrhagic telangiectasia (HHT). HHT causes abnormal, fragile blood vessels that bleed easily. The trial enrolled 33 adu…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA
Phase: PHASE2 • Sponsor: Hanny Al-Samkari, MD • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Could a daily pill stop HHT nosebleeds? new trial investigates.
Disease control OngoingThis study tests whether a low dose of the drug pazopanib, taken daily for 24 weeks, can reduce the severity and duration of nosebleeds in people with hereditary hemorrhagic telangiectasia (HHT). About 70 participants will receive either the active drug or a placebo. The research…
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA
Phase: PHASE2, PHASE3 • Sponsor: Cure HHT • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
HHT patients wanted for landmark registry study
Knowledge-focused OngoingThis study is creating a registry of up to 1,000 adults with Hereditary Hemorrhagic Telangiectasia (HHT) from four North American centers. Researchers will collect health information over time to learn how the disease changes and what factors affect those changes. The goal is to …
Matched conditions: HEREDITARY HEMORRHAGIC TELANGIECTASIA
Sponsor: Unity Health Toronto • Aim: Knowledge-focused
Last updated May 17, 2026 03:56 UTC